PYXS
Pyxis Oncology, Inc.
Key Financials
Operating Income
$-84420000
↑ 5.6%
Net Income
$-79621000
↓ 3.0%
Revenue
$13.9M
↓ 14.2%
EPS (Diluted)
$-1.28
↑ 3.0%
Total Liabilities
$38.1M
↑ 4.6%
Total Assets
$91.5M
↓ 41.8%
Cash & Equivalents
$15.4M
↓ 20.8%
Shareholders' Equity
$53.4M
↓ 55.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 7/2/2026 | View on SEC |
| 8-K | 7/2/2026 | View on SEC |
| SCHEDULE 13G/A | 7/2/2026 | View on SEC |
| 144 | 6/30/2026 | View on SEC |
| 8-K | 6/15/2026 | View on SEC |
| 10-Q | 5/14/2026 | View on SEC |
| 8-K | 5/14/2026 | View on SEC |
| ARS | 4/30/2026 | View on SEC |
| DEFA14A | 4/30/2026 | View on SEC |
| DEF 14A | 4/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PYXS |
| Company Name | Pyxis Oncology, Inc. |
| CIK | 1782223 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (617) 221-9059 |